Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.49 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.49 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558620 | 0.86 | RORC (0.49) | RORCSMN1; SMN2KDM4EMEN1MAPT | |
| SCHEMBL377917 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4094352 | 0.81 | KDM4E (0.51) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL29958034 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL1527112 | 0.81 | PKM (0.56) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4548035 | 0.80 | EPHX1 (0.70) | RORCSMN1; SMN2KDM4EMEN1MAPT | |
| SCHEMBL7055271 | 0.79 | MEN1 (0.50) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL31662881 | 0.79 | CA12 (0.48) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL29955042 | 0.79 | CA12 (0.48) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL4697903 | 0.78 | TDP1 (0.55) | KDM4EMEN1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143792-A1 | PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-07-22 | — | — | WO | disclosed |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-2399915-B1 | Process and intermediates for the preparation of aspartic acetal caspase inhibitors | VERTEX PHARMA (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-6541477-B2 | Treating inflammation and cardiac conditions with compositions containing acylated piperazine or piperidine rings coupled to phenyl and other aryl groups, such a furan or thiophene | SCIOS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6410540-B1 | HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-06-25 | — | — | US | disclosed |
| WO-1991012000-A1 | ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | MAP4K2, MAP4K5, MAP4K3 | RORC 1055/4885SMN1; SMN2 3826/4885KDM4E 1377/4885 |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | RORC 1108/4885SMN1; SMN2 1680/4885KDM4E 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.